CONNECTING Healthcare EXPERTISE

THE CLINICIAN EXCHANGE is a virtual exchange designed to pair specific clinical skillsets with specific industry initiatives.

EXCHANGE YOUR EXPERTISE

Learn how you can unlock the power of your expertise and experience to impact the healthcare industry in ways never before imagined

REGISTER NOWLEARN MORE

EXTEND, EXCEL…EXPLORE THE EXCHANGE

Learn how you can cost-effectively multiply your sales, education and R&D resources in an instant

REGISTER NOWLEARN MORE

COMMUNITY PORTAL

IN THE NEWS

CLINICIAN NEWS

Provided by: Medscape

From San Diego, A Great Debate on Biosimilars

Published: Tue, 21 Nov 2017 19:10:09 EST
Dr Jonathan Kay provides an overview of news and views on biosimilars to be presented at ACR 2017.
Medscape Rheumatology

FOURIER: Aim PCSK9 Inhibitors at Highest of High-Risk Patients?

Published: Tue, 21 Nov 2017 17:04:55 EST
"Not all of our patients with CV disease can have these expensive medications," says an observer. Subanalyses of FOURIER provide possible guides to their selective use in secondary prevention.
Medscape Medical News

Are You Considering Private Practice?

Published: Tue, 21 Nov 2017 16:39:18 EST
While private practice may never again dominate the healthcare landscape, it's likely to remain a small but permanent fixture.
Medscape Reader Polls
Displaying results 1-3 (of 20)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

HEALTHCARE SUPPLIER NEWS

Toxicity knocks Ardelyx's hyperkalemia hopes back to preclinic

Published: Tue, 21 Nov 2017 13:48:17 +0000
Unexpected side effects have spelled the end for Ardelyx’s drug candidate to treat elevated potassium levels in the blood, which was in phase 3 testing.

Cytokinetics cans lead drug after phase 3 ALS wipeout

Published: Tue, 21 Nov 2017 13:37:33 +0000
Cytokinetics has stopped development of its lead drug. The San Francisco-based biotech made the decision after tirasemtiv failed to beat placebo against the primary endpoint or any of the secondary goals in a study of more than 700 patients with amyotrophic lateral sclerosis (ALS).

Step Pharma bags cash for CTPS1 autoimmune R&D drive

Published: Tue, 21 Nov 2017 07:45:23 +0000
Step Pharma has closed a €14.5 million ($17.0 million) series A round. The financing equips the lean French biotech to prepare its CTPS1 inhibitors for clinical testing in autoimmune disorders.
Displaying results 1-3 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 

HAVE A QUESTION?

 Security code
1-800-4-the-clinx

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy
Top